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Serum periostin has recently emerged as a novel and useful
biomarker for bronchial asthma.1 Serum periostin is a surrogate
biomarker reﬂecting type 2 immune responses because periostin
is a downstreammolecule of interleukin-4 (IL-4) or IL-13, the signa-
ture cytokines of type 2 immune responses. This characteristic of
periostin can potentially be applied to predict the efﬁcacy of antag-
onists such as anti-IL-13 or anti-IgE antibodies against type 2 im-
mune responses. Furthermore, we have recently found that since
periostin reﬂects tissue remodeling or ﬁbrosis in bronchial asthma,
it can predict hypo-responsiveness to inhaled corticosteroids in
asthma patients, particularly in thosewho are late-onset and eosin-
ophil-dominant.2,3
In spite of the usefulness of periostin as a biomarker for bron-
chial asthma, serum periostin can be affected by periostin pro-
duced in sites other than lung tissues, particularly bones.
Therefore, it would be of great beneﬁt in caring for and treating
asthma patients if periostin in lung tissues could be speciﬁcally
detected. However, it remains obscure how periostin is secreted
from the cells and circulated in asthma patients. No study has
yet been performed to investigate whether periostin is secreted
in the bronchial lumens of asthma patients. Bronchial resident
cellsdepithelial cells, ﬁbroblasts, and endothelial cellsdare
assumed to be sources of periostin in lung tissues.4e6 It has
been demonstrated in vitro that periostin can be secreted from
the basal side, but not from the apical side, in bronchial epithelial
cells.4 These results negate the notion that periostin is secreted in
the bronchial lumens in asthma patients. In contrast, it has been
reported that periostin is highly detected in nasal lavage ﬂuid in
chronic rhinosinusitis patients, which may nevertheless support
this notion.7 Therefore, in this study, we examined periostin in
the bronchial lavage ﬂuid (BLF) of asthma patients to explore
whether it can be a more speciﬁc biomarker for bronchial
asthma.
Ten asthma patients and ten healthy donors were recruited
from the Iwate Medical University Hospital. Bronchial asthma
was diagnosed according to the criteria by Global Initiative for
Asthma, Global Strategy for Asthma Management and Prevention,
updated 2010. Spirometry was performed and airway methacho-
line responsiveness was measured using an Astograph (Jupiter
21, CHEST, Tokyo, Japan). The asthma patients had no otherPeer review under responsibility of Japanese Society of Allergology.
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subjects were nonallergic and nonsmokers. This study was
approved by the IwateMedical University Hospital Ethics Commit-
tee. The details of the asthma patients are described in Table 1. All
the asthma patients were well controlled with inhaled
corticosteroids.
Bronchial lavagewas performed by inserting a ﬂexible ﬁbreoptic
bronchoscope (Olympus; Olympus Optical Co Ltd, Tokyo, Japan) un-
der local anesthesia, as previously described.8 BLF was extracted
from one of the subsegmental bronchi of the left lingular division
by injection of 20 mL aliquots of sterile saline pre-warmed to
36.5 C twice and gently aspirated back into polypropylene tubes
kept on ice. We obtained 20e25 mL of BLF from each asthma pa-
tient. Immediately after lavage, mucus was removed from the ﬂuid
by ﬁltration through gauze, and the ﬂuid was then centrifuged at
200  g for 10 min at 4 C. The supernatant was decanted and
stored at 80 C. Ten mL of BLF supernatant was concentrated to
1.0 mL (ten-fold) by centrifugation using Centrifugal Filter Devices
(Amicon Ultra-0.5, Merck Millipore, Darmstadt, Germany). Perios-
tin in BLF was detected as previously described with a slight modi-
ﬁcation, using the biotin-stereptavidin system to increase the
sensitivity.2,9,10
The BLF from seven asthma patients showed no detectable peri-
ostin (data not shown). Although periostin was detectable in the
BLF of the remaining three asthma patients, the periostin levels
were less than 200 pg/mL. To quantify the tiny amounts of periostin
in BLF, we concentrated proteins in BLF by ten-fold. The original
periostin concentrations were estimated to be 7e511 pg/mL in
eight asthma patients by the ten-fold enriched BLF, and the remain-
ing two showed no detectable periostin (Table 1). When we
concentrated 100e150 mL of bronchoalveolar lavage ﬂuid (BALF)
from 10 normal donors by ten-fold, periostin concentrations were
estimated to be 78e648 pg/mL in nine normal donors and one
normal donor showed no detectable periostin (data not shown).
We were sure of these values because the detection limit of our
high-sensitivity periostin ELISA kit was as much as 3 pg/mL. The
value of the periostin concentration in BLF was signiﬁcantly lower
than the serum periostin concentrations, not only in asthma pa-
tients (n ¼ 734, median: 74.0 ng/mL, average: 82.1 ng/mL, SEM:
1.48, range: 14e440 ng/mL), but also in the normal donors
(n ¼ 302, median: 54.4 ng/mL, average: 53.9 ng/mL, SEM: 1.49,
range: 1e130 ng/mL).2,9,10 These results suggest that secretion of
periostin into the bronchial lumens of asthma patients does not
occur or is negligible. Secretion or production manner of periostin
in the lumensmay be different among the sites, because periostin isevier B.V. All rights reserved.
Table 1
Clinical backgrounds and periostin concentration in BLF in bronchial asthma patients.
Patient Age
(yr)
Sex Duration of asthma (yr) Allergic rhinitis Treatment Blood eosinophils
(/mL)
FEV1, % of predicted value FeNO
(ppb)
Periostin
(pg/mL)
1 48 M 11  FP 400 mg
MON 10 mg
390 72.6 25 7
2 41 M 38  FP 400 mg 296 63.0 34 148
3 72 M 65  FP 200 mg
SLM 100 mg
PRN 450 mg
251 48.1 39 310
4 43 M 40 þ FP 500 mg
SLM 100 mg
658 96.8 52 21
5 40 F 39  BUD 200 mg 341 78.5 30 N. D.
6 40 F 38  BUD 400 mg 179 59.1 46 N. D.
7 68 M 9  FP 200 mg 32 98 44 111
8 39 M 1 þ FP 100 mg 293 119.3 62 342
9 48 M 41  FP 200 mg 280 93.4 34 511
10 44 M 43 þ FP 500 mg
SLM 100 mg
285 71.1 134 41
FEV1, forced expiratory volume in 1 s; FeNO, fractional exhaled nitric oxide; FP, ﬂuticasone propionate; MON, montelukast sodium; SLM, salmeterol; PRN, pranlukast hydrate;
BUD, budesonide; N. D., not detected.
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patients.
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